|
![National Institute on Drug Abuse Clinical Trials Network](https://webarchive.library.unt.edu/eot2008/20090131003505im_/http://www.drugabuse.gov/CTN/images/CTN_sample_01.gif) |
|
|
Buprenorphine/Naloxone versus Clonidine for Opiate Dextoxification - INpatient (CTN 0001) |
Enrollment (Complete) |
Description
For decades clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs (NTPs). A new medication, buprenorphine, shows promise as an effective aid for opiate detoxification. However, little data have been generated for the shorter-term use of buprenorphine/naloxone for this indication. Since the diversity of clinics in the CTN provides an unparalleled opportunity to conduct such a clinical endeavor, the utility of buprenorphine/naloxone in short term (13 day) detoxification versus clonidine in an inpatient setting will be tested in the CTN.
|
|
For further information on clinical trials, click here. |
|
Available Brochures |
|
Patient Brochure |
.PDF |
.HTML |
|
You need Adobe Acrobat Reader in order to view the .pdf file.
Acrobat Reader can be downloaded for free from www.adobe.com. |
|
Principal Investigator : |
Walter Ling, M.D.
E-Mail : lwalter@ix.netcom.com
Phone : (310) 312-0500 |
|
|
NODES & CTPs: |
Pacific Region Node (Lead)
Betty Ford Center
Florida
Node
The Center for Drug-Free Living, Inc.
Operation PAR, Inc.
Great Lakes Regional Node
Self Help Addiction Rehabilitation (SHAR), Inc.
Long Island Node
Phoenix House
Ohio Valley Node
Maryhaven, Inc. |
|
|
|
|
|
|
|
|
|